SCHEMBL2162771

SCHEMBL2162771

Nc1ccc(-c2ccn3c(n2)nc2ccccc23)cc1OCCF

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD51 Q06609 3/20 0.41
MAPT P10636 2/20 0.35
BCHE P06276 2/20 0.35
ACHE P22303 2/20 0.35
FLT3 P36888 2/20 0.34
BMX P51813 1/20 0.34
KMT2A Q03164 2/20 0.33
TP53 P04637 1/20 0.33
HTT P42858 1/20 0.33
ADORA2A P29274 6/20 0.33
APP P05067 2/20 0.33
ADORA1 P30542 2/20 0.33
ROCK2 O75116 1/20 0.33
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
POLB P06746 1/20 0.32
HPGD P15428 1/20 0.32
MAPK1 P28482 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2162592 0.86 SMN1; SMN2 (0.39) RAD51MAPTFLT3BMXKMT2A
SCHEMBL2162679 0.83 FLT3 (0.45) RAD51MAPTFLT3BMXKMT2A
SCHEMBL2162673 0.82 RAD51 (0.46) RAD51MAPTKMT2ATP53HTT
SCHEMBL2163569 0.81 RAD51 (0.43) RAD51MAPTKMT2ATP53HTT
SCHEMBL2162664 0.79 RAD51 (0.40) RAD51ADORA2AADORA1
SCHEMBL12403623 0.77 ADORA2A (0.41) RAD51ADORA2AADORA1HSD17B10
SCHEMBL2163292 0.77 RAD51 (0.40) RAD51ADORA2AADORA1PKM
Bromide SCHEMBL2163717 0.76 ADORA2A (0.41) RAD51ADORA2AADORA1HSD17B10
SCHEMBL2163662 0.76 ATM (0.37) RAD51MAPTKMT2ATP53HTT
SCHEMBL12402976 0.75 KDM4E (0.44) RAD51MAPTFLT3KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2550255-B1 IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS LILLY CO ELI (US) 2016-04-27 EP disclosed
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-07-28 US disclosed
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-07-28 US disclosed
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110182812-A1 Imaging Agents for Detecting Neurological Disorders MAPT, APP, PSEN1 RAD51 1902/4885MAPT 1/4885BCHE 224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.